MDS-Bio1

Trial overview

Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS) and secondary disorders of haematopoiesis

Inclusion criteria

i) Patients with an abnormal blood count requiring investigation by blood and bone marrow sample.

ii) Patients known to have a blood disorder who are having a bone marrow sample taken as part of the assessment of that disorder.

Control subjects

Patients having elective orthopaedic surgery who have a normal blood count.

 

Exclusion criteria

i) Age < 18.

Controls

i) Age <18.

ii) On treatment likely to impair bone marrow function

iii) History of having had treatment likely to have impaired bone marrow function

Contact details

Principal Investigator

Prof. David Bowen

Tel 0113 2068481

Email david.bowen@leedsth.nhs.uk

Research Nurse

Catherine Levy

Tel 0113 2068577

Email catherine.levy@leedsth.nhs.uk



Other trials currently active for Myelodysplastic Syndromes

AML 17

The AML 17 trial has two distinct parts:

i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).

ii.For adults with acute promyelocytic leukaemia (APL).

 

REDDS

Red blood cell transfusion thresholds and QoL in myelodysplastic syndromes: a pilot, feasibility study


Tags

mds bone marrow haematopoiesis secondary disorders